Diabetes Drug SGLT-2 Inhibitors Show Promise in Reducing Kidney Stones
Research indicates that the diabetes drugs canagliflozin and dapagliflozin, which help the body expel excess fluid, can significantly reduce the risk of kidney stones and gout in patients. These SGLT-2 drugs, already known to lower the risk of early death and hospitalization in diabetics, are now suggested as a primary treatment option. The study from the University of British Columbia followed 20,000 diabetics and found a 30% reduction in the likelihood of developing these conditions, highlighting the potential of these drugs to improve the quality of life for diabetics.
